Six-Month Study Brings Hope To Cancer Patients
Cancer Research · Emerging Therapies
A landmark study of 122 cancer patients who self-reported their outcomes after taking a combination of ivermectin and mebendazole proved what science already knew but hid — these drugs work.
In a 6-month survey, cancer patients reported results that rival those of current traditional chemotherapy and radiation protocols. While these treatments have saved lives, they come with significant side effects, sometimes worse than the disease itself. Nearly half of the participants reported tumor regression or no current evidence of disease.
Whether used alone or alongside conventional therapies, these inexpensive off-label drugs demonstrate a high safety profile and are bringing real hope to the millions diagnosed with cancer each year.
Who Was in the Study?
The 122 participants represented a wide spectrum of cancer diagnoses. Respondents took compounded ivermectin with mebendazole at varying doses as recommended by their provider, and many combined the protocol with other interventions.
Cancer Types Represented
- Prostate cancer — 27.9%
- Breast cancer — 18.3%
- Lung cancer — 8.6%
- Colon cancer — 5.1%
- Liver cancer — 2.5%
- Other (urologic, pancreatic, thyroid, brain, melanoma, and more)
Additional Interventions Used by Participants
- Supplements such as vitamin D, turmeric, berberine, and medicinal mushrooms — 49.2%
- Dietary changes — 37.7%
- Chemotherapy — 27.9%
- Radiation — 21.3%
- Surgery — 19.7%
- Intermittent or prolonged fasting
- Ketogenic or low-sugar diets
- Hyperbaric oxygen therapy
- Red-light therapy
Ivermectin: Modulating and Controlling Cancer Growth
The unintended consequence of the COVID era was that ivermectin was proven to improve outcomes in other diseases — namely, SARS-CoV-2 and cancer. A 2025 review confirmed that ivermectin modulates multiple cancer-related pathways, offering a multifaceted approach to halting tumor progression.
Wnt/β-Catenin Pathway
Controls how cells grow, divide, and differentiate. In cancer, this pathway becomes abnormally "always on," driving uncontrolled growth. Ivermectin helps regulate it back toward normal function.
PI3K/Akt/mTOR Pathway
A major signaling cascade that tells cells when to grow, divide, and survive. By inhibiting this pathway in cancerous cells, ivermectin promotes cell death selectively in tumors.
STAT3 Regulation
STAT3 is a "master switch" protein that, in cancer, becomes stuck in the "on" position — driving tumor growth and resistance to cell death. Ivermectin helps reset this switch.
Chemotherapy Enhancement
Ivermectin has been shown to boost the effectiveness of certain chemotherapy drugs, potentially allowing lower doses and better outcomes when used in combination.
Spike Protein Binding
Studies suggest ivermectin may bind to the SARS-CoV-2 spike protein and inhibit cell entry. COVID-19 infection and vaccination have both been linked to a rise in certain cancers.
Mebendazole: Starving the Tumor, Stopping the Spread
Mebendazole is another anti-parasitic drug that shows remarkable promise in cancer treatment by cutting off what tumors need most: structural support, nutrients, and room to grow.
How Mebendazole Fights Cancer
- Disrupts microtubules — the internal "highways" cells use to transport materials and divide. Without them, tumor cells cannot grow or replicate normally.
- Triggers selective apoptosis — a controlled, orderly form of programmed cell death that breaks down cancer cells without damaging surrounding healthy tissue.
- Cuts off tumor blood supply — tumors build their own blood vessel networks to fuel rapid growth. Mebendazole selectively starves the tumor of this supply while preserving blood flow to healthy tissue.
Ivermectin + Mebendazole: Powerful Allies
When combined, the two drugs are more effective than either alone. They selectively target different tumor pathways, working in concert to reverse multidrug resistance — one of the most stubborn challenges in modern oncology. Although surgery and radiation therapy can be curative in early stages, they offer limited benefit in metastatic settings. This combination offers a meaningful option for patients across the spectrum.
A New Direction for Cancer Care
Whether using these inexpensive off-label drugs alone or alongside conventional therapies, their high safety profile and emerging efficacy data are offering genuine hope to the millions diagnosed with cancer annually. Speak with your provider about whether this protocol may be appropriate for your situation.
References
- Zhang, Y., & Wang, X. (2020). Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of Hematology & Oncology, 13(1), 165. https://doi.org/10.1186/s13045-020-00990-3
- Glaviano, A., et al. (2023). PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer, 22(1), 138. https://doi.org/10.1186/s12943-023-01827-6
- Tolomeo, M., & Cascio, A. (2021). The multifaced role of STAT3 in cancer and its implication for anticancer therapy. International Journal of Molecular Sciences, 22(2), 603. https://doi.org/10.3390/ijms22020603
- Barati, N., et al. (2022). Potential therapeutic effects of ivermectin in COVID-19. Experimental Biology and Medicine, 247(15), 1388–1396. https://doi.org/10.1177/15353702221099579
- Kuperwasser, C., & El-Deiry, W. S. (2026). COVID vaccination and post-infection cancer signals: Evaluating patterns and potential biological mechanisms. Oncotarget, 17, 1–29. https://doi.org/10.18632/oncotarget.28824
- National Center for Biotechnology Information. Microtubules. In: Molecular Biology of the Cell. https://www.ncbi.nlm.nih.gov/books/NBK9932/
- Cleveland Clinic. (2024, September 13). Apoptosis (Programmed Cell Death). Cleveland Clinic Health Library. https://my.clevelandclinic.org/health/articles/apoptosis
- Real-World Clinical Outcome Study — Ivermectin + Mebendazole. https://cdn.shopify.com/s/files/1/0649/7658/4920/files/Real-World_Clinical_Outcome_IVR_MEB.pdf
Author
This article is for informational purposes only and does not constitute medical advice. The study referenced is currently under preprint review and has not yet been peer-reviewed. Ivermectin and mebendazole are being used off-label in the context described. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment protocol. Individual results may vary.
